PT2061561E - Composições para tratar o cancro - Google Patents

Composições para tratar o cancro

Info

Publication number
PT2061561E
PT2061561E PT78373263T PT07837326T PT2061561E PT 2061561 E PT2061561 E PT 2061561E PT 78373263 T PT78373263 T PT 78373263T PT 07837326 T PT07837326 T PT 07837326T PT 2061561 E PT2061561 E PT 2061561E
Authority
PT
Portugal
Prior art keywords
compositions
treating cancer
cancer
hydroxylase
steroid
Prior art date
Application number
PT78373263T
Other languages
English (en)
Portuguese (pt)
Inventor
Alan H Auerbach
Arie S Belldegrun
Original Assignee
Janssen Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38916904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2061561(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Oncology Inc filed Critical Janssen Oncology Inc
Publication of PT2061561E publication Critical patent/PT2061561E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT78373263T 2006-08-25 2007-08-23 Composições para tratar o cancro PT2061561E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92150606P 2006-08-25 2006-08-25

Publications (1)

Publication Number Publication Date
PT2061561E true PT2061561E (pt) 2013-10-09

Family

ID=38916904

Family Applications (2)

Application Number Title Priority Date Filing Date
PT78373263T PT2061561E (pt) 2006-08-25 2007-08-23 Composições para tratar o cancro
PT121605869T PT2478907T (pt) 2006-08-25 2007-08-23 Composições para tratar o cancro

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT121605869T PT2478907T (pt) 2006-08-25 2007-08-23 Composições para tratar o cancro

Country Status (20)

Country Link
EP (3) EP2478907B1 (cg-RX-API-DMAC10.html)
JP (10) JP2010501575A (cg-RX-API-DMAC10.html)
KR (4) KR20090059126A (cg-RX-API-DMAC10.html)
CN (2) CN104306977A (cg-RX-API-DMAC10.html)
AU (6) AU2007287098C1 (cg-RX-API-DMAC10.html)
CA (1) CA2661422C (cg-RX-API-DMAC10.html)
CY (2) CY1115477T1 (cg-RX-API-DMAC10.html)
DK (2) DK2478907T3 (cg-RX-API-DMAC10.html)
ES (2) ES2428634T3 (cg-RX-API-DMAC10.html)
HR (2) HRP20130961T1 (cg-RX-API-DMAC10.html)
HU (1) HUE054495T2 (cg-RX-API-DMAC10.html)
IL (3) IL197211A0 (cg-RX-API-DMAC10.html)
LT (1) LT2478907T (cg-RX-API-DMAC10.html)
NO (2) NO20091190L (cg-RX-API-DMAC10.html)
NZ (1) NZ597830A (cg-RX-API-DMAC10.html)
PL (2) PL2061561T3 (cg-RX-API-DMAC10.html)
PT (2) PT2061561E (cg-RX-API-DMAC10.html)
RS (2) RS62034B1 (cg-RX-API-DMAC10.html)
SI (2) SI2061561T1 (cg-RX-API-DMAC10.html)
WO (1) WO2008024484A1 (cg-RX-API-DMAC10.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
HRP20130961T1 (hr) 2006-08-25 2013-11-22 Janssen Oncology, Inc. Kombinacije za tretman raka
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
US20100261689A1 (en) * 2007-10-29 2010-10-14 Masuo Yamaoka Pyrrolo [1,2-c] imidazole derivatives for use in the prophylaxis or treatment of cancer which is refractory to known cancer therapies
CN102558274B (zh) * 2010-12-08 2014-10-15 深圳万乐药业有限公司 一种适合工业化生产醋酸阿比特龙的合成方法
CN102558275A (zh) * 2010-12-20 2012-07-11 天津药物研究院 α型多晶型醋酸阿比特龙结晶、其制备方法、用途和药物组合物
BR112013017722A2 (pt) 2011-01-11 2016-07-12 Glaxosmithkline Llc combinação
FI2694072T4 (fi) 2011-04-01 2024-09-30 Genentech Inc Akt-inhibiittoriyhdisteen ja abirateronin yhdistelmä käytettäväksi terapeuttisissa hoidoissa
US20120295932A1 (en) * 2011-05-17 2012-11-22 Western Connecticut Health Network, Inc. Method for the treatment of cancer
CN103070828B (zh) * 2011-10-26 2016-01-27 山东新时代药业有限公司 一种含醋酸阿比特龙的固体分散体、片剂及其制备方法
CN102336801B (zh) * 2011-10-31 2013-05-15 南京卡文迪许生物工程技术有限公司 醋酸阿比特龙多晶型物和药用组合物
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
CA2872541A1 (en) * 2012-06-06 2013-12-12 Novartis Ag Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
WO2014052237A1 (en) 2012-09-26 2014-04-03 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
CN103800296A (zh) * 2012-11-13 2014-05-21 重庆医药工业研究院有限责任公司 一种稳定的阿比特龙口服固体药物组合物及其制备方法
EP2945628B1 (en) * 2013-01-15 2020-04-15 Aragon Pharmaceuticals, Inc. Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer
TWI686212B (zh) * 2013-03-15 2020-03-01 阿聯商太陽法瑪全球有限公司 醋酸阿比特龍配方
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
EP2983639A1 (en) * 2013-04-04 2016-02-17 Exelixis, Inc. Drug combinations to treat cancer
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
MX2016004267A (es) * 2013-10-01 2016-07-08 Novartis Ag Combinacion.
CA2923899A1 (en) * 2013-10-01 2015-04-09 Novartis Ag Enzalutamide in combination with afuresertib for the treatment of cancer
CN104546745A (zh) * 2013-10-14 2015-04-29 深圳海王药业有限公司 醋酸阿比特龙的片剂组合物及其制备工艺
EP3824908A1 (en) * 2015-04-10 2021-05-26 Capsugel Belgium NV Abiraterone acetate lipid formulations
WO2018023017A1 (en) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Methods of treating prostate cancer
EA201992430A1 (ru) * 2017-04-13 2020-02-28 Янссен Фармацевтика Нв Комбинированная терапия рака предстательной железы
KR20240096623A (ko) 2017-10-16 2024-06-26 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐
CN109718198A (zh) * 2017-10-30 2019-05-07 浙江京新药业股份有限公司 一种治疗前列腺癌的注射剂及其制备方法
CN114026106B (zh) * 2019-03-06 2025-01-21 普洛拉治疗公司 阿比特龙前药
WO2021031991A1 (zh) * 2019-08-16 2021-02-25 中国科学院分子细胞科学卓越创新中心 治疗激素依赖性疾病及减少激素依赖性疾病患者药物耐受的组合物和方法
US20230158047A1 (en) * 2020-04-16 2023-05-25 Tavanta Therapeutics Hungary Incorporated Methods and compositions for treating prostate cancer
CN114560903B (zh) * 2022-03-09 2023-08-01 绍兴市上虞区武汉理工大学高等研究院 一种阿比特龙衍生物的制备方法及其细胞毒性评价
LU506495B1 (en) 2024-03-01 2025-09-01 Alfasan Nederland B V 17alpha-HYDROXYLASE/17,20-LYASE (CYP17A1) INHIBITORS FOR THE TREATMENT OF SPONTANEOUS HYPERADRENOCORTICISM IN DOGS

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2138618T3 (es) 1992-03-31 2000-01-16 Btg Int Ltd Esteroides 17-sustituidos utiles en el tratamiento del cancer.
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
CA2401304A1 (en) * 2000-03-02 2001-09-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Combination chemotherapy
EP1351678A2 (en) * 2001-01-02 2003-10-15 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
WO2004037269A1 (en) * 2002-10-23 2004-05-06 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
EP1583539A2 (en) * 2003-01-13 2005-10-12 Cedars-Sinai Medical Center Paricalcitol as a chemotherapeutic agent
US20060030608A1 (en) * 2004-08-04 2006-02-09 Boehringer Ingelheim Pharmaceuticals, Inc. Anti aromatase compounds pharmaceutical compositions and uses thereof
GB0418900D0 (en) 2004-08-24 2004-09-29 Btg Int Ltd Novel salt forms
HRP20130961T1 (hr) 2006-08-25 2013-11-22 Janssen Oncology, Inc. Kombinacije za tretman raka

Also Published As

Publication number Publication date
HRP20130961T1 (hr) 2013-11-22
EP2478907A2 (en) 2012-07-25
KR20150108946A (ko) 2015-09-30
JP2019059750A (ja) 2019-04-18
JP2020114851A (ja) 2020-07-30
AU2007287098C1 (en) 2018-03-15
EP2478907A3 (en) 2012-08-01
HRP20210670T1 (hr) 2021-06-11
HK1131577A1 (en) 2010-01-29
EP2478907B1 (en) 2021-04-14
AU2007287098A1 (en) 2008-02-28
AU2015221447B9 (en) 2017-07-20
CN104306977A (zh) 2015-01-28
WO2008024484A1 (en) 2008-02-28
IL257681A (en) 2018-04-30
EP2061561A1 (en) 2009-05-27
CA2661422C (en) 2017-06-27
AU2015221447B2 (en) 2016-12-15
IL227746A0 (en) 2013-09-30
JP6053279B2 (ja) 2016-12-27
PL2478907T3 (pl) 2021-10-25
JP6740497B2 (ja) 2020-08-12
CY1115477T1 (el) 2017-01-04
JP2022185091A (ja) 2022-12-13
NZ597830A (en) 2013-02-22
AU2007287098B2 (en) 2013-08-15
CA2661422A1 (en) 2008-02-28
DK2061561T3 (da) 2013-10-07
AU2018271331A1 (en) 2018-12-20
KR20090059126A (ko) 2009-06-10
PL2061561T3 (pl) 2013-12-31
CY1124221T1 (el) 2022-05-27
JP2017052791A (ja) 2017-03-16
AU2015221447A1 (en) 2015-09-17
JP2010501575A (ja) 2010-01-21
PT2478907T (pt) 2021-05-26
AU2021201649A1 (en) 2021-04-08
EP2061561B1 (en) 2013-07-10
AU2017201764A1 (en) 2017-04-06
NO20200775A1 (no) 2009-03-20
JP6445123B2 (ja) 2018-12-26
ES2869343T3 (es) 2021-10-25
ES2428634T3 (es) 2013-11-08
CN101528308A (zh) 2009-09-09
SI2478907T1 (sl) 2021-08-31
JP2018065859A (ja) 2018-04-26
IL197211A0 (en) 2009-12-24
JP2015110577A (ja) 2015-06-18
DK2478907T3 (da) 2021-05-25
RS62034B1 (sr) 2021-07-30
KR20200125776A (ko) 2020-11-04
AU2022206696A1 (en) 2022-08-11
SI2061561T1 (sl) 2013-11-29
HUE054495T2 (hu) 2021-09-28
JP2021038252A (ja) 2021-03-11
LT2478907T (lt) 2021-06-25
NO20091190L (no) 2009-03-20
EP3804730A1 (en) 2021-04-14
KR20180003636A (ko) 2018-01-09
JP2024164147A (ja) 2024-11-26
RS52956B (sr) 2014-02-28
JP2012082215A (ja) 2012-04-26

Similar Documents

Publication Publication Date Title
EP2478907A3 (en) Methods and compositions for treating cancer
EP2425874A3 (en) Use of a vitamin D compound and an additional therapeutic agent for the treatment of cancer
WO2008021368A3 (en) Compositions and methods for neuroprotection
WO2007144152A3 (en) Extended step-down estrogen regimen
WO2010081032A3 (en) Steroidal compositions
WO2010088409A3 (en) Methods of neuroprotection using neuroprotective steroids and a vitamin d
UA94909C2 (ru) Фармацевтическая композиция нейроактивного стероида и ее применение
UA95310C2 (ru) Композиция, содержащая ингибитор chk1 и циклодекстрин, для лечения рака
WO2008022349A3 (en) Agents for blood-brain barrier delivery
MX347890B (es) Neuroproteccion y reparacion de melina usando progestina.
MX2010005119A (es) Corticosteroides para tratar la diarrea inducida por la epotilona o los derivados de epotilona.
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
WO2008011073A3 (en) Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
MX2009005335A (es) El uso de esteroides de pregnano y androstano para la fabricacion de una composicion farmaceutica para el tratamiento de trastornos del snc.
WO2007112403A3 (en) Prevention and treatment of ischemia-reperfusion injury
EP2023926A4 (en) PYRIDONECARBOXAMIDE DERIVATIVES USEFUL FOR TREATING HYPERPROLIFERATIVE AND ANGIOGENESIS RELATED DISORDERS
GB2479337A (en) Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent
WO2006089150A3 (en) Antiangiogenic agents with aldesleukin
MXPA02007117A (es) Composiciones para suministrar un antagonista de cortisol..
AR082998A1 (es) Asociacion farmaceutica para tratar y/o prevenir mioma y/o endometriosis, uso de resveratrol y progestogeno, composicion farmaceutica para tratamiento y/o prevencion de mioma y/o endometriosis, medicamento para tratamiento y/o prevencion de mioma y/o endometriosis, kit y metodo para tratamiento y/o prevencion de mioma y/o endometriosis
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
WO2010014595A3 (en) Methods and compositions for delivering therapeutic agents in the treatment of b-cell related disorders
WO2009138186A3 (de) SEQUENTIELLE VERARBEITUNG VON 20,20,21,21-PENTAFLUOR-17-HYDROXY-11β-[4-(HYDROXYACETYL) PHENYL] -19-NOR-17α-PREGNA-4,9-DIEN-3-ON UND EINEM ODER MEHREREN GESTAGENEN ZUR BEHANDLUNG GYNÄKOLOGISCHER ERKRANKUNGEN
WO2009035634A3 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
WO2005077968A8 (en) 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity